An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension
Phase of Trial: Phase II
Latest Information Update: 08 May 2017
At a glance
- Drugs IW 1973 (Primary)
- Indications Cardiovascular disorders
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 08 May 2017 Data from this trial are expected in the second half of 2017, according to an Ironwood Pharmaceuticals media release.
- 01 Mar 2017 Status changed to recruiting.
- 28 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Apr 2017.